Phase 2 trial data shows strong immune response and better tolerance in over-70s
- Coronavirus – latest updates
- See all our coronavirus coverage
The University of Oxford is expected to release data on the efficacy of its coronavirus vaccine candidate in the coming weeks, with the latest trial results suggesting it produces a strong immune response in older adults.
The ChAdOx1 nCov-2019 vaccine has been shown to trigger a robust immune response in healthy adults aged 56-69 and over 70.